Minerva Neurosciences(NASDAQ) NERV

Minerva Neurosciences, Inc. makes medicines for brain and nerve disorders. It helps people living with schizophrenia and Parkinson's disease. Its products treat symptoms that other drugs might miss.

Treating the Human Brain

• Roluperidone: Investigational drug for schizophrenia; currently in a Phase 3 trial involving 380 patients.
• MIN-301: Soluble protein variant studied for Parkinson's disease and other neurodegenerative conditions.
• Seltorexant Royalties: Potential payments for an insomnia treatment co-developed with Janssen; royalty rights sold to Royalty Pharma.

The Path to Market Approval

• Submitted a New Drug Application for roluperidone in August 2022.
• Received an FDA Complete Response Letter on Feb. 26, 2024.
• Closed an $80 million private placement of preferred stock on Oct. 23, 2025.
• Screened the first patient for a new Phase 3 clinical trial on March 31, 2026.
• Entered an agreement for a $75 million at-the-market stock offering on May 27, 2026.

A Different Kind of Symptom

Minerva focuses on treating the "negative" symptoms of schizophrenia, like social withdrawal and lack of emotion. Most current therapies only target "positive" symptoms, such as hallucinations or delusions. This strategy aims to fill a significant gap in the current mental health market.

Counting the Costs of Discovery

• Net loss reached $107.9 million for the six-month period ended June 30, 2026.
• Research and development costs were $12.4 million in the first half of 2026.
• Cash and marketable securities totaled $75.4 million as of June 30, 2026.
• Market capitalization was $258.6 million in the second quarter of 2026, up 1886.6% year over year.
• Non-GAAP adjusted net loss was $15.1 million for the six months ended June 30, 2026.

Evolution of a Clinical Firm

Minerva has transitioned from early discovery to late-stage clinical trials for its lead candidate. The company continues to fund operations through equity deals while navigating the regulatory path for its primary treatments.